EUVIMEDEUVIMED entdecken
Kohortenstudie

Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study

Yoshinori Ikehata iD, Naotaka Nishiyama, Satoshi Ishida, Hiroshi Kitamura

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyaf167 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Yoshinori Ikehata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Toyama, 2630 Sugitani, Toyama, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Biomarkers, Tumor. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Bladder cancer is a prevalent and costly malignancy characterized by significant heterogeneity in presentation and clinical outcomes. This study aimed to classify the molecular subtypes of bladder cancer using immunohistochemistry (IHC) and to evaluate the prognosis, treatment responsiveness, and clinical utility of IHC-based subtype classification.

Methods

We retrospectively reviewed the data of 84 patients with bladder cancer who underwent radical cystectomy. Immunohistochemistry was performed using the markers CK5/6, CK14, CK20, GATA3, and UPK2. Molecular subtypes were identified through hierarchical clustering, and statistical analyses were conducted to evaluate cancer-specific survival (CSS) and recurrence-free survival (RFS).

Results

Among the 68 patients included in the final analysis, 52 were classified as luminal type and 16 as basal type. The 5-year CSS and RFS were 76.2% and 64.2%, respectively. Among patients who received platinum-based neoadjuvant chemotherapy, those with the luminal subtype showed significantly better RFS than those with the basal subtype (P = 0.016, HR 5.27, 95%CI 1.15–24.1). However, no significant difference in CSS was observed between the luminal and basal subtypes.

Conclusions

Molecular subtypes can be inferred using common immunohistochemical markers, providing a practical approach for personalized treatment strategies. Further prospective studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyBiomarkers, TumorHumansFemaleMaleRetrospective StudiesImmunohistochemistryAgedMiddle AgedPrognosisAged, 80 and overAdult

Stichwörter der Autor:innen

bladder cancerimmunohistochemistrymolecular subtyperadical cystectomy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, University of Toyama, 2630 Sugitani, Toyama, Japan.

ORCID-Profile: Yoshinori Ikehata

Zitieren

APA

Ikehata, Y., Nishiyama, N., Ishida, S., & Kitamura, H. (2026). Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf167

Vancouver

Ikehata Y, Nishiyama N, Ishida S, Kitamura H. Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf167

BibTeX
@article{Ikehata2026,
  author = {Ikehata, Yoshinori and Nishiyama, Naotaka and Ishida, Satoshi and Kitamura, Hiroshi},
  title = {Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyaf167}
}
Kostenlos starten →